| Type | Title | Date Released | |
|---|---|---|---|
6-K | Immutep Quarterly Activities Report & Appendix 4C Q1 FY27 | ||
6-K | Immutep Receives A$2.16 million French R&D Tax Incentive | ||
20-F | Form 20-F | ||
6-K | Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement | ||
6-K | Immutep Announces Change to American Depositary Share (ADS) Ratio to Regain Nasdaq Minimum Bid Price Compliance | ||
6-K | Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) | ||
6-K | Immutep Limited FY2026 Preliminary Final Report | ||
6-K | Immutep Reports Q4 FY26 Financial Results and Clinical Progress | ||
6-K | Immutep Reports Positive Mature Overall Survival Data for INSIGHT-003 and Provides TACTI-004 Update | ||
6-K | Immutep Reports Positive Interim Phase I Data for First-in-Class LAG-3 Agonist IMP761 | ||
LETTER | Form LETTER | ||
6-K | Immutep Discontinues TACTI-004 Phase III Trial Following Futility Analysis |
